Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
Platforms like CoverWell provide an added layer of safety that helps patients stay on therapy while minimizing risks
Linagliptin also interacts with the S2' subsite
If you eat fish, try to eat fatty fish at least once or twice a week
Endocrinology, 158 , 42184232